UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028148
Receipt number R000032218
Scientific Title The development of treatment using decoded neurofeedback for patients with PTSD
Date of disclosure of the study information 2017/07/15
Last modified on 2023/05/09 05:53:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The development of treatment using decoded neurofeedback for patients with PTSD

Acronym

The development of treatment using decoded neurofeedback for patients with PTSD

Scientific Title

The development of treatment using decoded neurofeedback for patients with PTSD

Scientific Title:Acronym

The development of treatment using decoded neurofeedback for patients with PTSD

Region

Japan


Condition

Condition

Post-traumatic stress disorder (PTSD)

Classification by specialty

Psychiatry Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A main purpose of this clinical trial is to evaluate safety and efficacy of fMRI neurofeedback applied to PTSD.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase I,II


Assessment

Primary outcomes

Clinician-Administered PTSD scale

Key secondary outcomes

Skin conductance response to traumatic stimuli
Amygdala response to traumatic stimuli


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

fMRI neurofeedback using a 3T fMRI apparatus

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

50 years-old >=

Gender

Male and Female

Key inclusion criteria

1. DSM-IV-TR diagnosis of PTSD
2. Normal visual acuity
4. Aged 20-50 years-old, outpatients,
5. Capability of informed consent

Key exclusion criteria

Implanted cardiac pacemaker
Surgical aneurysm clips
Neurostimulator
Implanted pumps
Metal fragments in body/eyes
Tattoos or permanent eyeliner (if ink contains metallic specks)
Treatment history of ECT
Diagnosis of neurological disorders (including epilepsy), substance dependence, or
significant cardiac disease
History of neurological disorders (including epilepsy), substance dependence, or head injury with loss of consciousness
Pregnancy. Suspicion of pregnancy. Breast-feeding. Incapability of contraception during experiment. Doctors diagnose danger.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Tetsufumi
Middle name
Last name Kanazawa

Organization

Osaka Medical and Pharmaceutical University

Division name

Neuropsychiatry

Zip code

569-8686

Address

2-7 Daigaku-machi, Takatsuki-city, Osaka, Japan

TEL

072-683-1221

Email

tk@ompu.ac.jp


Public contact

Name of contact person

1st name Tetsufumi
Middle name
Last name Kanazawa

Organization

Osaka Medical and Pharmaceutical University

Division name

Neuropsychiatry

Zip code

569-8686

Address

2-7 Daigaku-machi, Takatsuki-city, Osaka, Japan

TEL

072-683-1221

Homepage URL


Email

tk@ompu.ac.jp


Sponsor or person

Institute

Osaka Medical and Pharmaceutical University

Institute

Department

Personal name



Funding Source

Organization

Osaka Medical and Pharmaceutical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Advanced Telecommunications Research Institute International (ATR)
National defense medical college
Japan ground self-force, Test and evaluation command, Military Medicine Research Unit
Self-Defense Forces Central Hospital
Kokoro to Karada Hikarinohana clinic
Seven mental clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka Medical and Pharmaceutical College

Address

2-7 Daigaku-machi, Takatsuki-city, Osaka, Japan

Tel

072-683-1221

Email

rinri@ompu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 07 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2017 Year 06 Month 01 Day

Date of IRB

2017 Year 07 Month 03 Day

Anticipated trial start date

2017 Year 07 Month 20 Day

Last follow-up date

2027 Year 07 Month 19 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 07 Month 09 Day

Last modified on

2023 Year 05 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032218


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name